Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

NCT03475953 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT03475953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03475953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Lead sponsor
Institut Bergonié
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 4, 2018
Completion date
December 31, 2025
Enrollment
747 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, colorectal cancer not msi-h or mmr-deficient, gastro-enteropancreatic neuroendocrine tumor, gist, hepatocellular carcinoma, hpv-related carcinoma, mesotheliomas pleural, non-small cell lung cancer, oesophageal or gastric carcinoma, renal carcinoma, soft-tissue sarcoma, solid tumor, adult, thyroid cancer, triple negative breast cancer, urothelial carcinoma